-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c
-
-
-
-
-
-
-
Trevi (TRVI) First to Show Positive IPF Chronic Cough, RCC Data - Cantor Fitzgerald
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Falls to LOD, Down ~7pct, Raymond James: 'This is a clean win and Haduvio has now set the bar in IPF-CC'
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Tops Q1 EPS by 4c
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) PT Raised to $12.50 at H.C. Wainwright
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Trevi Therapeutics (TRVI)
-
416,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

